Hologic, Inc. (NASDAQ:HOLX) Position Reduced by HB Wealth Management LLC

HB Wealth Management LLC cut its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 12.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,032 shares of the medical equipment provider’s stock after selling 742 shares during the period. HB Wealth Management LLC’s holdings in Hologic were worth $360,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Belpointe Asset Management LLC grew its stake in Hologic by 18.0% during the 1st quarter. Belpointe Asset Management LLC now owns 937 shares of the medical equipment provider’s stock valued at $76,000 after acquiring an additional 143 shares in the last quarter. Deseret Mutual Benefit Administrators raised its holdings in shares of Hologic by 42.2% during the third quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock worth $36,000 after acquiring an additional 155 shares in the last quarter. Cooper Financial Group boosted its position in Hologic by 1.9% during the third quarter. Cooper Financial Group now owns 9,502 shares of the medical equipment provider’s stock valued at $659,000 after purchasing an additional 174 shares during the last quarter. Kinneret Advisory LLC grew its stake in Hologic by 2.3% in the first quarter. Kinneret Advisory LLC now owns 7,867 shares of the medical equipment provider’s stock valued at $604,000 after purchasing an additional 176 shares in the last quarter. Finally, Captrust Financial Advisors increased its position in Hologic by 2.8% in the 1st quarter. Captrust Financial Advisors now owns 6,636 shares of the medical equipment provider’s stock worth $510,000 after purchasing an additional 181 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on HOLX shares. Raymond James lifted their price target on Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. Needham & Company LLC increased their price target on shares of Hologic from $83.00 to $90.00 and gave the stock a “buy” rating in a research note on Friday, February 2nd. UBS Group lifted their price objective on shares of Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a research note on Friday, February 2nd. William Blair reissued an “outperform” rating on shares of Hologic in a research report on Friday, February 2nd. Finally, StockNews.com downgraded Hologic from a “buy” rating to a “hold” rating in a research note on Friday, March 8th. Six research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $86.89.

Hologic Price Performance

Hologic stock opened at $77.35 on Thursday. The business has a 50 day simple moving average of $74.73 and a 200 day simple moving average of $71.84. Hologic, Inc. has a one year low of $64.02 and a one year high of $87.88. The company has a market capitalization of $18.16 billion, a PE ratio of 36.66, a price-to-earnings-growth ratio of 2.56 and a beta of 1.00. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.89 and a quick ratio of 3.18.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.03. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $989.32 million. During the same period last year, the business earned $1.07 earnings per share. The business’s revenue was down 5.7% on a year-over-year basis. On average, sell-side analysts forecast that Hologic, Inc. will post 4.02 EPS for the current fiscal year.

Insider Activity at Hologic

In other Hologic news, Director Scott T. Garrett sold 16,441 shares of the business’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the transaction, the director now owns 48,611 shares of the company’s stock, valued at $3,670,130.50. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, Director Scott T. Garrett sold 16,441 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the sale, the director now owns 48,611 shares of the company’s stock, valued at $3,670,130.50. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Charles J. Dockendorff sold 1,465 shares of the business’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $76.21, for a total value of $111,647.65. Following the sale, the director now owns 1,572 shares of the company’s stock, valued at approximately $119,802.12. The disclosure for this sale can be found here. Insiders sold 32,846 shares of company stock valued at $2,473,443 in the last three months. Corporate insiders own 1.75% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.